Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study.

Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, Calori G, Kang SM, Sahakyan L, Sanosyan A, Vitale C, Marazzi G, Margonato A, Belardinelli R.

Int J Cardiol. 2013 Mar 10;163(3):320-5. doi: 10.1016/j.ijcard.2012.09.123.

PMID:
23073279
2.

Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.

Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, Ragogna F, Arioli F, Bassanelli G, Spoladore R, Luzi L, Margonato A, Perseghin G.

Heart. 2011 Sep;97(18):1495-500. doi: 10.1136/hrt.2011.226332.

PMID:
21700755
3.

Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry.

Kim JS, Kim CH, Chun KJ, Kim JH, Park YH, Kim J, Choi JH, Lee SH, Kim EJ, Yu DG, Ahn EY, Jeong MH.

Clin Res Cardiol. 2013 Dec;102(12):915-22. doi: 10.1007/s00392-013-0611-0.

PMID:
23982468
4.

Is treatment with trimetazidine beneficial in patients with chronic heart failure?

Zhou X, Chen J.

PLoS One. 2014 May 5;9(5):e94660. doi: 10.1371/journal.pone.0094660. Review.

5.

Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis.

Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, Ge J.

J Am Coll Cardiol. 2012 Mar 6;59(10):913-22. doi: 10.1016/j.jacc.2011.11.027. Review.

6.

A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.

Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A.

J Am Coll Cardiol. 2006 Sep 5;48(5):992-8.

7.
8.

Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.

Marazzi G, Wajngarten M, Vitale C, Patrizi R, Pelliccia F, Gebara O, Pierri H, Ramires JA, Volterrani M, Fini M, Rosano GM.

Int J Cardiol. 2007 Aug 9;120(1):79-84.

PMID:
17134770
9.
10.

Effects of trimetazidine, a partial inhibitor of fatty acid oxidation, on ventricular function and survival after myocardial infarction and reperfusion in the rat.

Mouquet F, Rousseau D, Domergue-Dupont V, Grynberg A, Liao R.

Fundam Clin Pharmacol. 2010 Aug;24(4):469-76. doi: 10.1111/j.1472-8206.2009.00802.x.

PMID:
20030737
11.

Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect.

Belardinelli R, Solenghi M, Volpe L, Purcaro A.

Eur Heart J. 2007 May;28(9):1102-8.

12.

Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure.

Cera M, Salerno A, Fragasso G, Montanaro C, Gardini C, Marinosci G, Arioli F, Spoladore R, Facchini A, Godino C, Margonato A.

J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):24-30. doi: 10.1177/1074248409356431.

PMID:
20100903
13.

Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.

Belardinelli R, Lacalaprice F, Faccenda E, Volpe L.

Eur J Cardiovasc Prev Rehabil. 2008 Oct;15(5):533-40. doi: 10.1097/HJR.0b013e328304feec.

PMID:
18797405
14.

Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study.

Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GM.

Int J Cardiol. 2013 Sep 30;168(2):1078-81. doi: 10.1016/j.ijcard.2012.11.001.

PMID:
23200272
15.

The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.

Onay-Besikci A, Guner S, Arioglu E, Ozakca I, Ozcelikay AT, Altan VM.

Can J Physiol Pharmacol. 2007 May;85(5):527-35.

PMID:
17632588
16.

[Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].

Fedorova TA, Il'ina IuV, Sotnikova TI, Rybakova MK.

Klin Med (Mosk). 2004;82(11):15-20. Russian.

PMID:
15656392
17.

Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A.

Am Heart J. 2003 Nov;146(5):E18.

PMID:
14597947
18.

Effects of trimetazidine in nonischemic heart failure: a randomized study.

Winter JL, Castro PF, Quintana JC, Altamirano R, Enriquez A, Verdejo HE, Jalil JE, Mellado R, Concepción R, Sepúlveda P, Rossel V, Sepúlveda L, Chiong M, García L, Lavandero S.

J Card Fail. 2014 Mar;20(3):149-54. doi: 10.1016/j.cardfail.2014.01.004.

PMID:
24412523
19.

Randomized clinical trial France DMLA2: effect of trimetazidine on exudative and nonexudative age-relatedmacular degeneration.

Cohen SY, Bourgeois H, Corbe C, Chaine G, Espinasse-Berrod MA, Garcia-Sanchez J, Gaudric A, Hullo A, Leys A, Soubrane G, Sahel J.

Retina. 2012 Apr;32(4):834-43. doi: 10.1097/IAE.0b013e31822058a3.

PMID:
21822162
20.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators..

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
Items per page

Supplemental Content

Support Center